ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY ), is an innovative medical technology company focused on addressing the critical unmet needs of women around the world and a broader community. the interior of the office, space, and new. therapeutic and diagnostic products, announced that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a panel discussion at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior CEO, Head of Biotechnology Research at Maxim Group. The meeting will be held approximately October 15 – 17, 2024.
Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the summit.
About Femasys
Femasys is a leading medical company focused on addressing the critical unmet needs of women worldwide. with extensive in-office data, space, and new medical and surgical solutions, including a leading sales representative and FDA cleared product. FemaSeed® Intratubal Insemination, a new infertility treatment designed to place sperm directly at the site of conception, has been approved by the FDA and has received regulatory approval in Canada and Europe. FemBloc® permanent delivery at the end of the hospital’s development is the one and only without surgery, in the office, ensuring the Prescribing is a safe option for women at a much lower cost than other long-term surgeries. The Company has developed related products and obtained regulatory approvals to sell them in the United States, Canada, Europe, and other foreign territories. of the United States, and is commercially ready due to its in-house manufacturing capabilities. Its proven products include FemVue® and FemVue® Mini for ultrasound examination of the skin, which can be used together with FemCath®a colonoscopy for cervical cancer screening, and FemCerv®an endocervical biopsy sample for cervical cancer screening. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Information
This press release contains forward-looking statements that involve significant risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “may,” “should,” “expect,” “plan,” “anticipate,” “could,” “expect,” ” expect,” “believe,” “recommend,” “potential,” “anticipate,” or “continue” or the negative of these or other similar terms, although not all statements are forward-looking. forward-looking statements are based on our current expectations and are subject to uncertainties, risks and assumptions, many of which are beyond our control. control, are difficult to predict and could cause actual results to differ materially from those we expect. In addition, certain forward-looking statements are based on assumptions about future events. Factors that could cause actual results to differ include, among others: our ability to develop and advance our existing product candidates and programs, and successful initiation, enrollment and completion of medical studies; the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates and other positive results; Estimates of the total market contact for our products and product representatives; our ability to commercialize our products and substitute products, or the impact of delays in selling our products, including FemaSeed; our business models and strategic plans for our products, technologies and businesses, including our implementation; and other risks and uncertainties described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. The forward-looking statements contained in this press release are made as of today, and Femasys undertakes no obligation to update such statements unless required under applicable law.
Communication:
Investor:
Matt Blazei
IR@femasys.com
Advertisement:
Central Waldenburg
Media@femasys.com
#Femasys #Participate #Webcast #Maxim #Healthcare #Virtual #Summit